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###### Translational perspective

Neutrophils are involved in the pathophysiology of infracted coronary arteries in STEMI via NET structures. Platelets, activated by thrombin, are required for NET formation, while the integrity of NET scaffold contributes to the functionality of NET-bound TF. The blockage of NET formation or local neutralization of NET-mediated TF signalling constitutes candidate therapeutic targets.

Introduction {#s1}
============

Atherosclerotic plaque rupture in epicardial coronary arteries and subsequent thrombus formation is a localized, catastrophic event that leads to vessel occlusion in cases of acute ST-segment elevation myocardial infarction (STEMI). Tissue factor (TF), the major *in vivo* initiator of coagulation,^[@EHV007C1]^ is critical in arterial thrombosis.^[@EHV007C2]^ In this regard, the presence of circulating or blood-borne TF, derived from microparticles, monocytes, and myeloid cells has been reported.^[@EHV007C3]^

The role of polymorphonuclear neutrophils (PMNs) in thrombosis is supported by studies showing significant attenuation of thrombus formation in neutropenic mice.^[@EHV007C2],[@EHV007C4]^ However, the ability of neutrophils to trigger *in vivo* thrombotic events via production of TF, is a matter of debate.^[@EHV007C5]--[@EHV007C7]^

Recently, the ability of PMNs to generate Neutrophil Extracellular Traps (NETs) which contain extracellular chromatin networks 'decorated' with neutrophil granular and cytoplasmic proteins,^[@EHV007C8]^ offered a novel view regarding their role in thromboinflammation. Neutrophils and NETs have been linked to thrombosis via various mediators of thrombotic process.^[@EHV007C9]^ The ability of PMNs to expose functional TF on NETs^[@EHV007C7],[@EHV007C10],[@EHV007C11]^ identifies them as a source of TF in the interaction between innate immunity, inflammation, and coagulation.^[@EHV007C2],[@EHV007C4],[@EHV007C12],[@EHV007C13]^ Although platelets are involved in the formation of NETs^[@EHV007C14]^ and are abundantly present in arterial thrombi, their link through PMNs in arterial atherothrombosis is still under investigation.

We show here for the first time that PMNs recruited at the site of plaque rupture during STEMI, become activated following platelet--neutrophil interactions and release NETs decorated with functional TF. TF functionality is dependent on the presence of intact NET structures. NET release in STEMI appears to be a two-step phenomenon in which initial intracellular TF up-regulation in PMNs is followed by the generation of TF-bearing NETs.

Methods {#s2}
=======

Patients {#s2a}
--------

Patients with STEMI (*n* = 18) eligible for primary percutaneous revascularization and individuals with normal coronary angiogram on diagnostic coronary angiography used as controls (*n* = 13), were recruited in the present study. Patients on cardiogenic shock, on chronic dual antiplatelet therapy, history of angina or previous STEMI, with critical stenosis in other coronary arteries and blood disorders, severe hepatic or renal dysfunction, diabetes mellitus, as well as ongoing chronic inflammatory, autoimmune, or malignant diseases were excluded. Patients were transferred immediately at the catheterization laboratory and received unfractionated heparin and aspirin plus ticagrelor oral loading. The study protocol was in accordance with the Declaration of Helsinki and was approved by the Ethics Review Board of the University Hospital of Alexandroupolis. Written informed consent was obtained from each individual.

Selective sampling from the infarct-related coronary artery (IRA) was performed with a dedicated catheter (Export^®^ AP Aspiration Catheter, Medronic Vascular, Danvers, MA, USA). Blood from the non-infarct-related (non-culprit) healthy vessels of STEMI patients (non-IRA) and from control individuals was obtained after coronary ostium engagement, through 6F diagnostic coronary catheters during primary PCI or diagnostic catheterization, respectively. Blood from the IRA, the non-IRA of STEMI patients, and from coronary arteries of control individuals was collected and used for isolation of PMNs, platelets, and plasma within 30--45 min after the transfer to the catheterization laboratory. The mode of sample collection did not affect results concerning NET generation.

Clinical characteristics of patients and conditions of sampling are described in detail in [Supplementary material online,](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1) Methods and [*Table S1*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1).

Experimental procedures {#s2b}
-----------------------

Mediators and conditions used for stimulation/inhibition studies, immunofluorescence and FACS experiments, NET structures and protein isolation, MPO/DNA and thrombin-antithrombin (TAT) complex ELISAs, immunoblotting and mRNA analyses are described in detail in [Supplementary material online](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1).

Statistical analysis {#s2c}
--------------------

Data are presented as box charts (means ± SD). Statistical analyses were performed using one-way ANOVA (Scheffé test in uniform *n* and least significant difference test in non-uniform *n* for *post-hoc* comparisons). All statistical analyses were performed with OriginPro 8. *P*-values \<0.05 were considered significant.

Results {#s3}
=======

Neutrophil extracellular traps are accumulated in infarct-related coronary arteries of patients with ST-segment elevation acute myocardial infarction {#s3a}
-----------------------------------------------------------------------------------------------------------------------------------------------------

We observed *ex vivo* PMNs releasing NETs isolated from blood samples obtained by IRA aspiration in STEMI patients (*n* = 18); significant differences were observed compared with non-infarct-related coronary arteries (non-IRA) from the same patients (*n* = 18), and to control individuals (controls; *n* = 13), as demonstrated by confocal microscopy \[myeloperoxidase/neutrophil elastase (MPO/NE) immunofluorescense, *Figure [1](#EHV007F1){ref-type="fig"} A* and *B*\], extracellular DNA levels (*Figure [1](#EHV007F1){ref-type="fig"}C*), and MPO/DNA complex ELISA in isolated NET structures (*Figure [1](#EHV007F1){ref-type="fig"}D*). The NET-specific marker MPO/DNA complex was also elevated in plasma samples obtained from IRA compared with non-IRA or controls (*Figure [1](#EHV007F1){ref-type="fig"}E*), and it was not correlated with TIMI flow grade (see [Supplementary material online, *Figure S2*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)). Figure 1Polymorphonuclear neutrophils of patients with ST-segment elevation acute myocardial infarction release neutrophil extracellular traps at the site of plaque rupture. (*A*) Neutrophil extracellular traps of polymorphonuclear neutrophils obtained from infarct-related coronary artery, non-infarct-related coronary artery, and control individual coronary arteries/ctrl art (confocal microscopy). (*B*) Percentage of neutrophil extracellular trap-releasing polymorphonuclear neutrophils, (*C*) extracellular deoxyribonucleic acid levels, (*D*) myeloperoxidase--deoxyribonucleic acid complex in isolated neutrophil extracellular trap structures obtained by selective coronary sampling. (*E*) Myeloperoxidase--deoxyribonucleic acid complex levels in plasma samples obtained from coronary arteries of ST-segment elevation acute myocardial infarction patients and control individuals (least significant difference test was used only in *E*). (*F*) Neutrophil extracellular traps visualized in thrombus specimens from patients with ST-segment elevation acute myocardial infarction as extracellular structures decorated with myeloperoxidase and citrulinated H3 (confocal microscopy). Green: myeloperoxidase; red: (*A*) NE, (*F*) cit-H3; blue: 4′,6-diamidino-2-phenylindole/deoxyribonucleic acid. One representative out of six (*A*) or nine (*F*) independent experiments is shown. Original magnification: (*A*) ×600, (*F*) ×400. Scale bar: 5 μm. Box edges for chart boxes of all figures demonstrate mean ± SD. For (*B*), (*C*), (*D*), *n* = 6. 

Accordingly, thrombi contained high numbers of neutrophils either in the form of dense neutrophilic islets (more than 40% coverage of the thrombus, [Supplementary material online, *Figure S3*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*A*) or areas with extensive presence of NETs, (*Figure [1](#EHV007F1){ref-type="fig"}F*, [Supplementary material online, *Figure S3*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*B*, *n* = 9).

In patients with STEMI who had undergone spontaneous thrombus resolution (*n* = 4), MPO/DNA complex levels in plasma from IRA were found significantly lower compared with patients who formed stable thrombi (*Figure [1](#EHV007F1){ref-type="fig"}E*, *n* = 14). Furthermore, residual thrombotic material aspirated from patients who underwent spontaneous thrombus resolution demonstrated almost absence of NETs and very low numbers of intact neutrophils (see [Supplementary material online, *Figure S3*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*A* and *B*, *n* = 4).

The local NET release in the IRA of STEMI patients points to them as a possible key player in the pathogenesis of the disease.

Intracellular tissue factor in polymorphonuclear neutrophils of ST-segment elevation acute myocardial infarction patients is not always associated with neutrophil extracellular traps {#s3b}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Considering the key role of TF in thrombosis, we investigated the presence of TF on NETs from patients with STEMI. NETs generated *ex vivo* from PMNs isolated from IRAs were decorated with TF (*Figure [2](#EHV007F2){ref-type="fig"}A* and *B*). Furthermore, thrombus specimens demonstrated PMNs and NETs with TF localization, as observed by TF/NE co-localization in confocal microscopy, whereas residual thrombotic material from patients who underwent spontaneous thrombus resolution was characterized by almost complete absence of TF expressing sites (*Figure [2](#EHV007F2){ref-type="fig"}C*). Figure 2Functional tissue factor is localized in neutrophil extracellular traps generated in infarct-related coronary artery of patients with ST-segment elevation acute myocardial infarction. (*A*) Localization of tissue factor in polymorphonuclear neutrophils obtained after selective coronary sampling, (confocal microscopy). (*B*) Tissue factor immunoblotting and integrated optical density of neutrophil extracellular trap proteins. (*C*) Tissue factor on neutrophil extracellular traps in thrombi specimens from patients with ST-segment elevation acute myocardial infarction, is co-localized with NE extracellularly, (confocal microscopy). Green: tissue factor; red: NE; blue: 4′,6-diamidino-2-phenylindole/deoxyribonucleic acid. One representative out of six (*A*) or nine (*C*) independent experiments is shown. Original magnification: ×600. Scale bar: 5 μm. (*D*) Tissue factor immunoblotting and integrated optical density ratio of tissue factor to glyceraldehyde 3-phosphate dehydrogenase in polymorphonuclear neutrophil lysates. (*B*), (*D*) One representative out of three independent experiments is shown. (*E*) Tissue factor messenger ribonucleic acid expression in polymorphonuclear neutrophils (*n* = 6) obtained by selective coronary sampling. (*F*) Thrombin levels in control plasma incubated with isolated neutrophil extracellular trap structures from polymorphonuclear neutrophils obtained by selective coronary sampling. Neutralizing anti-tissue factor antibody was used to inhibit tissue factor-mediated thrombin generation. DNase was used for neutrophil extracellular trap scaffold degradation. Phorbol myristate acetate-induced neutrophil extracellular trap structures in control polymorphonuclear neutrophils were used as negative control. (*G*) Fluorescence-activated cell-sorting analysis of Annexin V and CD62P in control platelets stimulated with control plasma pre-treated with isolated neutrophil extracellular trap structures from polymorphonuclear neutrophils obtained by selective coronary sampling. FLLRN peptide was used as a PAR-1 antagonist. For (*F*) and (*G*) *n* = 4.

Although NET generation appeared to be a localized phenomenon observed exclusively in the IRA, we observed intracellular TF up-regulation in intact PMNs isolated from both IRA and non-IRA of STEMI patients but not from control individuals, as assessed by immunofluorescence (*Figure [2](#EHV007F2){ref-type="fig"}A*) and immunoblotting of neutrophil lysates (*Figure [2](#EHV007F2){ref-type="fig"}D*) and flow cytometry (see [Supplementary material online, *Figure S4*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)). The observed up-regulation of *TF* mRNA levels followed a pattern similar to that of protein levels, indicating significant increase of TF expression in PMNs from both IRA and non-IRA of STEMI patients compared with control individuals (*Figure [2](#EHV007F2){ref-type="fig"}E*).

These findings suggest that although circulating PMNs of patients with STEMI express intracellular TF, its local exposure in IRA is mediated by NETs.

Tissue factor expressed on neutrophil extracellular traps from infarct-related coronary artery needs the deoxyribonucleic acid scaffold to activate the coagulation cascade {#s3c}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TF-thrombin axis has a dual functional role; thrombus formation and signalling *via* PARs. To study the prothrombotic activity of TF expressed on NETs at the sites of plaque rupture, thrombin levels were analysed with TAT complex ELISA. We observed increased TAT levels after incubation of control plasma with NETs isolated from IRA (*Figure [2](#EHV007F2){ref-type="fig"}F*). However, TAT levels were normal (*Figure [2](#EHV007F2){ref-type="fig"}F*) after incubation of control plasma with either NETs isolated from non-IRA or healthy individuals or 'vacant of TF'-NETs (see [Supplementary material online, *Figure S5*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)) generated *in vitro* by phorbol myristate acetate (PMA)-stimulated control PMNs. The increase in thrombin levels was TF-dependent as demonstrated by inhibition with specific neutralizing anti-TF antibody (*Figure [2](#EHV007F2){ref-type="fig"}F*).

We next assessed the effects of TF-bearing NETs on control platelet activation via PAR signalling. Incubation of control platelets with control plasma pre-treated with IRA-derived NET structures exhibited more pronounced expression of activation markers (Annexin V, CD62P), compared with platelets incubated with control plasma pre-treated with NET structures obtained from non-IRAs or control individuals (*Figure [2](#EHV007F2){ref-type="fig"}G*). The observed up-regulation of platelet activation markers was TF -dependent as demonstrated by inhibition with specific neutralizing anti-TF antibody (*Figure [2](#EHV007F2){ref-type="fig"}G*). Moreover, treatment with a PAR-1 antagonist blunted the effect on platelets, demonstrating that NET-bound TF is also able to induce PAR-1 activation, through thrombin generation (*Figure [2](#EHV007F2){ref-type="fig"}G*).

Prompted by reports in which DNase I interfered in the function of protein components of NETs^[@EHV007C4],[@EHV007C15],[@EHV007C16]^ and considering its therapeutic applications in NET-associated diseases,^[@EHV007C17],[@EHV007C18]^ we tested whether DNase I affects the functionality of NET-bound TF. Treatment with DNase I abolished thrombin generation in control plasma (*Figure [2](#EHV007F2){ref-type="fig"}F*) and further platelet activation (*Figure [2](#EHV007F2){ref-type="fig"}G*).

These data indicate that NETs expose functional TF, able to induce both thrombin generation and platelet activation. NET structure integrity appears to be involved in measurements of TF functionality.

Plasma from infarct-related coronary artery is able to induce tissue factor *in vitro* but not neutrophil extracellular traps {#s3d}
-----------------------------------------------------------------------------------------------------------------------------

We assessed the effect of IRA- and non-IRA-obtained plasma on PMN TF expression and NET release *in vitro*. Control PMNs treated with plasma from IRA or non-IRA demonstrated a similar pattern of intracellular TF increase in both mRNA and protein level in contrast to treatment with plasma from control individuals that showed no TF up-regulation, as observed by immunofluorescence, real time qRT--PCR, immunoblotting (*Figure [3](#EHV007F3){ref-type="fig"}A*--*C*), and flow cytometry (*Figure [3](#EHV007F3){ref-type="fig"}D*). However, no significant increase of NET generation was observed in conditions similar to all previous experiments (*Figure [3](#EHV007F3){ref-type="fig"}A* and *E*). Figure 3The microenvironment in infarct-related coronary artery induces tissue factor expression but not neutrophil extracellular trap generation in polymorphonuclear neutrophils. (*A*) Neutrophil extracellular trap generation in control polymorphonuclear neutrophils treated with infarct-related coronary artery plasma, non-infarct-related coronary artery plasma, and plasma obtained from control individuals (confocal microscopy). Green: tissue factor; red: NE; blue: 4′,6-diamidino-2-phenylindole/deoxyribonucleic acid. One representative out of four independent experiments is shown. Original magnification: ×600. Scale bar: 5 μm. (*B*) Tissue factor *mRNA*, (*C*) tissue factor immunoblotting and integrated optical density according to glyceraldehyde 3-phosphate dehydrogenase, and (*D*) fluorescence-activated cell-sorting analysis with relative MFIs in control polymorphonuclear neutrophils treated with plasma obtained by selective coronary sampling. (C) Unstimulated polymorphonuclear neutrophils and lipopolysaccharide-stimulated peripheral blood mononuclear cells were used as negative and positive controls for tissue factor, respectively. One representative out of four independent experiments is shown. (*E*) Myeloperoxidase--deoxyribonucleic acid complex in isolated neutrophil extracellular trap structures from control polymorphonuclear neutrophils treated with plasma obtained by selective coronary sampling. For (*B*), (*C*), (*D*), (*E*) *n* = 4.

These data indicate that although TF-bearing NETs are formed in the vicinity of plaque rupture, intracellular up-regulation of TF in neutrophils is a generalized phenomenon in patients with STEMI.

Platelets activated in the environment of infarct-related coronary artery are able to induce neutrophil extracellular trap formation {#s3e}
------------------------------------------------------------------------------------------------------------------------------------

Based on the ability of activated platelets to induce NET release in other disease states,^[@EHV007C14]^ we investigated whether activated platelets from the IRA of STEMI patients are able to induce NETs. First, platelets from IRA demonstrated increased levels of surface activation markers compared with platelets from non-IRA or control individuals, as observed by Annexin V and CD62P flow cytometry analysis (*Figure [4](#EHV007F4){ref-type="fig"}A* and *B*, [Supplementary material online, *Figure S6*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*A* and *B*). Moreover, increased number of platelet/neutrophil aggregates (CD61/CD66b double-positive events) was observed in PMNs isolated from IRA compared with non-IRA or control individuals (*Figure [4](#EHV007F4){ref-type="fig"}C*). Figure 4Activated platelets from infarct-related coronary artery are responsible for neutrophil extracellular trap generation. Fluorescence-activated cell-sorting analysis of Annexin V (*A*) and CD62P (*B*) on infarct-related coronary artery platelets, non-infarct-related coronary artery platelets and control individual coronary artery platelets. (*C*) Platelet/polymorphonuclear neutrophil aggregates observed as double-positive CD61/CD66b per 10 000 CD66b positive events with fluorescence-activated cell-sorting analysis in polymorphonuclear neutrophils isolated after selective coronary sampling. (*D*) Percentage of neutrophil extracellular trap-releasing polymorphonuclear neutrophils and (*E*) Neutrophil extracellular trap generation by control polymorphonuclear neutrophils treated with platelets isolated after selective coronary sampling, (confocal microscopy). Green: tissue factor; red: NE; blue: 4′,6-diamidino-2-phenylindole/deoxyribonucleic acid. Original magnification: ×600. Scale bar: 5 μm. (*F*) myeloperoxidase--deoxyribonucleic acid complex in isolated neutrophil extracellular trap structures of control polymorphonuclear neutrophils treated with platelets obtained by coronary sampling. (*A*), (*B*), (*C*), (*D*), (*F*) *n* = 4. (*E*) One representative out of four independent experiments is shown.

These data indicate activation of platelets at the site of plaque rupture and suggest increased interaction locally with PMNs.

We then tested whether activated platelets play a role in NET generation in the IRA. Control PMNs treated with IRA-derived platelets showed increased NET release (*Figure [4](#EHV007F4){ref-type="fig"}D*--*F*), while treatment of PMNs with platelets derived from non-IRA or control individuals did not induce NET formation. Interestingly, NETs generated by activated platelets in the absence of additional IRA-derived plasma demonstrated absence of TF exposure (*Figure [4](#EHV007F4){ref-type="fig"}E*).

We further observed that IRA-derived plasma was able to activate control platelets *in vitro* in contrast to non-IRA-derived or control plasma (*Figure [5](#EHV007F5){ref-type="fig"}A* and *B* and [Supplementary material online, *Figure S6*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*A* and *B*). Similar to IRA-derived platelets, *in vitro*-activated platelets induced the generation of TF-free NETs from control PMNs (*Figure [5](#EHV007F5){ref-type="fig"}C*--*E*). Figure 5The microenvironment in infarct-related coronary artery activates platelets for subsequent neutrophil extracellular trap generation in polymorphonuclear neutrophils. Fluorescence-activated cell-sorting analysis of Annexin V (*A*) and CD62P (*B*) on control platelets treated with plasma obtained by selective coronary sampling. (*C*), (*D*), (*E*) Neutrophil extracellular trap formation by control polymorphonuclear neutrophils incubated with control platelets pre-treated with plasma obtained by selective coronary sampling. (*C*), (*D*) Confocal microscopy and (*E*) myeloperoxidase--deoxyribonucleic acid complex on neutrophil extracellular trap structures. (*F*) Neutrophil extracellular trap generation after stimulation of control polymorphonuclear neutrophils with plasma from infarct-related coronary artery of ST-segment elevation acute myocardial infarction patients and control platelets pre-treated with infarct-related coronary artery plasma (confocal microscopy). (*G*) Thrombin levels in control plasma incubated with isolated neutrophil extracellular trap structures from control polymorphonuclear neutrophils stimulated as in (*F*). Anti-tissue factor antibody was used to neutralize tissue factor-mediated thrombin generation. DNase I was used for neutrophil extracellular trap scaffold degradation. (*C*) and (*F*) Green: tissue factor; red: NE; blue: 4′,6-diamidino-2-phenylindole/deoxyribonucleic acid. One representative out of four independent experiments is shown. Original magnification: ×600. Scale bar: 5 μm. For (*A*), (*B*), (*D*), (*E*), (*G*) *n* = 4.

In view of the above findings, the complementary roles of plasma and platelets in the formation of TF-bearing NETs were further investigated by a two-step experimental procedure. The first step was the intracellular expression of TF in control PMNs after stimulation with plasma obtained from STEMI patients (IRA or non-IRA-derived plasma). The second step was NET generation in these TF-loaded PMNs after adding activated platelets, either IRA-isolated platelets or *in vitro*-activated platelets as described earlier (*Figure [5](#EHV007F5){ref-type="fig"}F*). NETs derived from this *in vitro* procedure were also able to induce thrombin generation in a TF-axis-dependent manner, while dismantling of NET scaffold with DNase I abolished the TF-driven TAT measurement (*Figure [5](#EHV007F5){ref-type="fig"}G*).

This suggests that the generation of TF-expressing NETs follows a two-step process that requires both circulating inflammatory stimuli present in the plasma of STEMI patients and activated platelets primarily present in the vicinity of ruptured plaque.

Thrombin in plasma from infarct-related coronary artery is responsible for platelet activation and subsequent neutrophil extracellular trap generation {#s3f}
------------------------------------------------------------------------------------------------------------------------------------------------------

Since thrombin is able to activate platelets through PARs,^[@EHV007C19]^ we investigated the involvement of thrombin in the local activation of IRA platelets. First we measured the levels of thrombin in patients with STEMI and in control individuals. Thrombin levels were elevated in IRA-derived plasma compared with non-IRA-derived plasma or plasma obtained from control individuals (*Figure [6](#EHV007F6){ref-type="fig"}A*). Moreover, platelet activation by IRA-derived plasma was thrombin-depended (which mainly signals through PAR-1), as shown by adding thrombin inhibitors antithrombin III or dabigatran, as well as by specific PAR-1 antagonism (*Figure [6](#EHV007F6){ref-type="fig"}B* and *C*, [Supplementary material online, *Figure S6*](http://eurheartj.oxfordjournals.org/lookup/suppl/doi:10.1093/eurheartj/ehv007/-/DC1)*A* and *B*). Furthermore, thrombin inhibition in IRA plasma also attenuated the subsequent NET release by control PMNs incubated with platelets activated with this plasma (*Figure [6](#EHV007F6){ref-type="fig"}D*). These data were also reproduced by using recombinant thrombin to activate control platelets (*Figure [6](#EHV007F6){ref-type="fig"}B*--*D*), while thrombin was unable to induce NET release in control PMNs by itself (*Figure [6](#EHV007F6){ref-type="fig"}D*). In addition, thrombin inhibition blocked the *in vitro* activation of platelets making them unable to induce NETs in control PMNs treated with IRA-derived plasma (*Figure [6](#EHV007F6){ref-type="fig"}D*) as well as prevented TF externalization as observed by immunoblotting of NET proteins (*Figure [6](#EHV007F6){ref-type="fig"}E*). Figure 6Elevated levels of thrombin in plasma from infarct-related coronary artery are responsible for the local activation of platelets and subsequent neutrophil extracellular trap generation. (*A*) Thrombin levels in plasma obtained by selective coronary sampling (*n* = 9, each), as assessed by TAT complex enzyme-linked immunosorbant assay. Fluorescence-activated cell-sorting analysis of Annexin V (*B*) and CD62P (*C*) on control platelets treated with plasma from infarct-related coronary artery in the presence or not of thrombin (antithrombin III or dabigatran) and PAR-1 signalling (FLLRN) inhibitors. Recombinant thrombin was used as positive control. (*D*) Myeloperoxidase--deoxyribonucleic acid complex enzyme-linked immunosorbant assay in neutrophil extracellular traps derived after stimulation of control polymorphonuclear neutrophils with plasma from infarct-related coronary artery of ST-segment elevation acute myocardial infarction patients and control platelets pre-treated with infarct-related coronary artery plasma, in the presence or absence of thrombin inhibitors (antithrombin III or dabigatran). (*E*) Immunoblotting and integrated optical density of tissue factor in neutrophil extracellular trap proteins derived from *in vitro* stimulation of control polymorphonuclear neutrophils, as described previously in (*D*), in the presence or absence of dabigatran. One representative out of four independent experiments is shown. For (*B*), (*C*), (*D*), *n* = 4.

These data indicate that thrombin in the environment of IRA plasma is a key mediator for the activation of platelets and the ensuing NET generation.

Discussion {#s4}
==========

Using selective coronary sampling, we could demonstrate for the first time the local accumulation of TF-bearing NETs at the site of coronary thrombosis. We observed blood neutrophils releasing NETs and exposing TF in the IRA but not in the non-IRA of STEMI patients. Moreover, and in agreement with the findings of others,^[@EHV007C20],[@EHV007C21]^ we observed islets of PMNs and NETs decorated with TF in thrombi obtained from IRAs. The exposed TF on NETs is functional and capable of inducing both thrombin generation and thrombin/PAR1-mediated platelet activation. NET scaffold integrity is necessary for TF functionality and the formation of NETs is driven by thrombin-activated platelets in STEMI.

We showed that the microenvironment in the circulation of STEMI patients promotes the expression of TF by PMNs. We observed the presence of 'non-NETotic' TF-loaded PMNs in non-IRA of STEMI patients. Additionally, we were able to reproduce intracellular TF up-regulation *in vitro* by culturing control PMNs with plasma from both IRA and non-IRA of STEMI patients, but not with plasma from control individuals. We suggest that inflammatory mediator(s) induce neutrophil-derived circulating TF in STEMI patients. Although, various cytokines have been charged as TF inducers,^[@EHV007C5],[@EHV007C11],[@EHV007C22]^ further studies are needed to identify them in STEMI.

The ability of neutrophils to induce *in vivo* thrombosis by production of TF, is a matter of debate.^[@EHV007C5]--[@EHV007C7]^ However, the discovery of NETs upgraded their prothrombotic role.^[@EHV007C13]^ Neutrophilic TF, regardless of its origin, acquired or produced or both, is trafficked on NETs making neutrophils a source of active TF. The neutrophilic source of TF has been recently described;^[@EHV007C2]^ the formation of NET locally exposes the TF already present in cells, at the sites of plaque rupture; in contrast the formation of NETs in sepsis is systemic with subsequent dissemination of TF.^[@EHV007C10]^ As previous studies have demonstrated the involvement of NETs in thrombosis through further coagulation mediators, such as Factor XII,^[@EHV007C4]^ more experiments are required to reveal a possible crosstalk of these molecules with TF on the NET scaffold.

Despite the absence of TF on the surface of PMNs, as assessed by flow cytometry,^[@EHV007C5]^ we provide evidence suggesting that the TF exposed on NETs of STEMI patients is functional, able to induce thrombin generation. The generated thrombin can further activate resting platelets through PAR cell signalling, since PAR-1 antagonism attenuated this effect. Accordingly to previous studies suggesting the crucial role of NET integrity in the functionality of proteins epitopes,^[@EHV007C15]^ we found that TF-dependent thrombin generation is abolished when NETs are dismantled with DNase I. In accordance, treatment with recombinant human DNase I significantly improves outcome after arterial thrombotic events in mice.^[@EHV007C23]^

Activated platelet--neutrophil interactions have been previously shown to induce NET release.^[@EHV007C14],[@EHV007C24]^ In the present study, we found that activated platelets obtained from IRA and *in vitro*-activated platelets by IRA-derived plasma are able to induce NET formation in control neutrophils *in vitro*. The increased thrombin levels found in the IRA and the significant attenuation of platelet-induced NET generation by thrombin inhibitors and PAR blockers suggests a possible role for thrombin in the process. We suggest that activated platelet-PMN interplay continues to generate thrombin, thus supporting thrombogenesis through NETs even after initial thrombus expansion, which limits the ability of plaque-derived TF to migrate in the core of the developing thrombus.^[@EHV007C25]^

In conclusion, we show here for the first time the interaction between activated platelets and TF-loaded neutrophils at sites of atherosclerotic plaque rupture for the release of active TF-bearing NETs in humans with acute STEMI (*Figure [7](#EHV007F7){ref-type="fig"}*). A variety of inflammatory stimuli in STEMI promote the *de novo* expression of TF in neutrophils. In parallel, locally activated platelets interact with neutrophils for the release of TF-bearing NETs inside the culprit artery. The functionality of TF depends on the integrity of the NET structure and is able to induce thrombin generation and platelet activation, creating a possible vicious cycle that leads to thrombus propagation and stability. The observation that NETs are involved in TF functionality and thrombus stability may trigger further research for novel therapeutic targets. Figure 7Two 'hit' tissue factor/neutrophil extracellular trap model in ST-segment elevation acute myocardial infarction. Schematic representation. Platelets are activated by thrombin in infarct-related coronary artery and interact with polymorphonuclear neutrophils, resulting in neutrophil extracellular traps formation (second step) and exposure of pre-existing tissue factor in polymorphonuclear neutrophils (first step).
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